Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives

Area of Science:

• Neurodegenerative diseases
• Microbiology
• Gut-brain axis research

Background:

• Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder with limited treatment options.
• Gut dysbiosis and gut-brain axis (GBA) dysfunction are increasingly recognized as potential contributors to ALS.
• Alterations in gut microbial composition are observed in ALS patients and correlate with disease progression.

Purpose of the Study:

• To review current literature on gut dysbiosis in ALS.
• To explore the role of GBA dysfunction in ALS pathogenesis.
• To examine the therapeutic potential of microbiota-modulating agents for ALS.

Main Methods:

• Comprehensive literature review of studies on ALS, gut microbiota, and GBA.
• Analysis of mechanisms linking gut dysbiosis to ALS pathology.
• Examination of preclinical data on prebiotics, probiotics, and postbiotics in ALS models.

Main Results:

• Gut dysbiosis contributes to ALS through compromised intestinal barrier integrity, metabolic dysfunction, and immune dysregulation.
• Preclinical studies demonstrate neuroprotective effects of targeting the gut microbiota in ALS models.
• Modulating the gut microbiota shows promise in alleviating motor symptoms and slowing disease progression in animal models.

Conclusions:

• Gut dysbiosis and GBA dysfunction are significant factors in ALS.
• Targeting the gut microbiota represents a promising therapeutic avenue for ALS.
• Further research is needed to translate findings from animal models to human ALS patients.